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Introduction: Uveitis is an inflammatory eye disorder which may elevate intraocular 
pressure (IOP), causing sight-threatening glaucoma. Treatment of refractory uveitic 
glaucoma involves implantation of a glaucoma drainage device (GDD). Uveitic 
glaucoma has been a minority diagnosis in prior studies comparing the valved Ahmed 
GDD and non-valved Baerveldt GDD. Here we compare the safety and efficacy of the 
Ahmed and Baerveldt GDD in uveitic glaucoma.
 
 
Methods: This retrospective comparative study was conducted on patients with uveitic 
glaucoma (≥14 years old) who underwent Ahmed or Baerveldt GDD implantation 
between 2006–2018 with a minimum follow-up of 3 months. Success was defined as 
IOP of 6-21 mmHg with (complete success) or without (qualified success) medications, 
with at least light perception vision and no further glaucoma surgery. Pearson Chi-
squared test, independent t test, and Kaplan-Meier survival model were utilized for 
statistical analysis.  
Results: 137 eyes of 122 patients (67 Ahmed and 70 Baerveldt) were included. 
Baseline characteristics were comparable in both groups. The Baerveldt group 
experienced greater IOP reduction (60.3% vs. 44.5%), higher complete success rate 
(28.6% vs. 10.4%), higher complication rate (44.3% vs. 20.9%), and higher hypotony 
rate (10% vs. 0%) than the Ahmed group (all p values <0.05).  
Discussion: Our results are in line with pooled analysis of previous GDD comparison 
studies on various types of glaucoma. For patients with uveitic glaucoma, the Baerveldt 
implant provided a significantly higher success rate and greater IOP reduction with 
fewer medications, but was associated with a higher complication rate, compared to the 
Ahmed implant. 
 
 
 
 
 
 
